Torsade de pointes

Clinical Cardiology

Volumn 16, Issue 9, 1993, Pages 683-686

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiarrhythmic drugs; long QT syndrome; polymorphic tachycardia; proarrhythmia; QT interval; torsade de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COTRIMOXAZOLE; DISOPYRAMIDE; ERYTHROMYCIN; ISOPRENALINE; KETANSERIN; LIDOCAINE; MAGNESIUM; MEXILETINE; NEUROLEPTIC AGENT; PENTAMIDINE; POTASSIUM; PROBUCOL; PROCAINAMIDE; QUINIDINE; SOTALOL; TERFENADINE; TERODILINE; THIORIDAZINE; TOCAINIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL FEATURE; DRUG METABOLISM; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART PACING; HEART RATE; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

ADRENERGIC BETA-ANTAGONISTS; ANIMAL; ANTI-ARRHYTHMIA AGENTS; ANTIPSYCHOTIC AGENTS; DOGS; ELECTROCARDIOGRAPHY; ERYTHROMYCIN; HEART RATE; HISTAMINE ANTAGONISTS; HUMAN; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 0027320035     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.4960160910     Document Type: Article

References (29)

1. Congenital deaf‐mutism, functional heart disease with prolongation of the Q‐T interval and sudden death
2. A new familial cardiac syndrome in children
3. Aritmie cardiache rare dell'eta pediatrica
4. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias
5. La tachycardie ventriculaire a deux foyers opposes variables
6. True and false torsade de pointes (letter)
7. Torsade de pointes versus polymorphous ventricular tachycardia
8. Incidence and clinical features of the quinidineassociated long QT syndrome: Implications for patient care
9. Torsades de pointes: The long‐short initiating sequence and other clinical features: Observations in 32 patients
10. The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis
11. Quinidine‐induced ventricular flutter and fibrillation without digitalis therapy
12. Incidence, type, and dose‐dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF (abstr)
13. Amiodarone in patients with previous drug‐mediated torsade de pointes
14. Amiodarone and torsades de pointes
15. A randomized, double‐blind, placebo‐controlled dose‐ranging study of intravenous UK‐68,798 (dofetilide) in patients with inducible sustained ventricular tachyarrhythmias
16. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias
17. Long QT syndrome and torsades de pointes: Basic and clinical aspects
18. Mechanism of the cardio‐toxic actions of terfenadine
19. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length
20. Brady‐cardia‐dependent triggered activity: Relevance to drug‐induced multiform ventricular tachycardia
21. Treatment of torsade de pointes with magnesium sulfate
22. The long QT syndrome
23. Ventricular tachyarrhythmias related to early afterdepolarizations and triggered firing: Relationship to QT interval prolongation and potential therapeutic role for calcium channel blocking agents
24. Frequency‐dependent interactions of mexiletine and quinidine in canine cardiac Purkinje fibers
25. Modification of the frequency‐ and voltage‐dependent effects of quinindine when administered in combination with tocainide in canine Purkinje fibers
26. Efficacy of permanent pacing in the management of high‐risk patients with long QT syndrome
27. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents
28. Time‐dependent outward current in guinea pig myocytes: Gating kinetics of the delayed rectifier
29. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras‐1 gene